Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TYR | P14679 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5475178 | 0.81 | PDK2 (0.38) | MAPTLMNAPDK2AKR1B1KDM4E | |
| SCHEMBL5474650 | 0.80 | CYP19A1 (0.35) | NPC1MAPTRAB9ALMNA | |
| SCHEMBL14363429 | 0.79 | CHRNA1 (0.37) | NPC1MAPTRAB9ALMNAPDK2 | |
| SCHEMBL7322612 | 0.70 | CHRM3 (0.45) | MAPTLMNAPDK2 | |
| SCHEMBL25490549 | 0.70 | TSHR (0.48) | TSHRNPC1MAPTRAB9AHSD17B2 | |
| SCHEMBL25491224 | 0.70 | TSHR (0.48) | TSHRNPC1MAPTRAB9AHSD17B2 | |
| SCHEMBL27317130 | 0.68 | PDK2 (0.40) | TSHRNPC1MAPTRAB9ALMNA | |
| SCHEMBL27783841 | 0.67 | PDK2 (0.42) | TSHRNPC1MAPTRAB9ALMNA | |
| SCHEMBL6509446 | 0.67 | MAPT (0.38) | MAPTLMNAAKR1B1KDM4E | |
| SCHEMBL24471521 | 0.67 | PDK2 (0.41) | TSHRNPC1MAPTRAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276139-A1 | Substituted Pixyl Protecting Groups for Oligonucleotide Synthesis | ISIS PHARMACEUTICALS, INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070276139-A1 | Substituted Pixyl Protecting Groups for Oligonucleotide Synthesis | ISIS PHARMACEUTICALS, INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070276139-A1 | Substituted Pixyl Protecting Groups for Oligonucleotide Synthesis | ISIS PHARMACEUTICALS, INC. | 2007-11-29 | — | — | US | disclosed |
| WO-2005077966-A1 | SUBSTITUTED PIXYL PROTECTING GROUPS FOR OLIGONUCLEOTIDE SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276139-A1 | Substituted Pixyl Protecting Groups for Oligonucleotide Synthesis | RPP30, NOP10, NR0B1 | TSHR 1002/4885NPC1 2191/4885MAPT 4786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.